Ignite Creation Date:
2024-05-06 @ 3:12 PM
Last Modification Date:
2024-10-26 @ 1:45 PM
Study NCT ID:
NCT04556461
Status:
COMPLETED
Last Update Posted:
2023-04-21
First Post:
2020-07-16
Brief Title:
Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function
Sponsor:
Prof Dr Stephan Weidinger
Organization:
University Hospital Schleswig-Holstein
Study Overview
Official Title:
Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function
Status:
COMPLETED
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TraSki
Brief Summary:
Effects of tralokinumab treatment of atopic dermatitis on skin barrier function
Detailed Description:
A phase II monocenter open investigator initiated clinical trial investigating the effects of Tralokinumab treatment of atopic dermatitis on skin barrier physiology and function
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None